Skip To Main Content
Barry Hafkin on Muck Rack

Barry Hafkin

As seen in: BioRxiv, American Society for Microbiology (ASM), ASM Journals
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barry

Contact Barry, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis

|
By Barry Hafkin, Khisimuzi Mdluli, Nader Fotouhi
| ASM Journals
Antimicrobial Chemotherapy Research Article INTRODUCTION Despite recent advances in the development of new drugs against tuberculosis (TB), major challenges exist for the treatment of rifampin-resistant (RR-) TB. Linezolid (LZD), the first oxazolidinone antibacterial drug to reach the market, has been repurposed to treat RR-TB and is now designated as a preferred drug for this indication by the WHO (1).
Open in Who Shared Issue with article?

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis

|
By Deepak V. Almeida, Si-Yang Li, Jin Lee, Barry Hafkin
| BioRxiv
New Results doi: https://doi.org/10.1101/2023.06.18.545492 Abstract Contezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in treatment of drug-resistant tuberculosis.
Open in Who Shared Issue with article?

In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

|
By Michael Cynamon, Carolyn Shoen, Michelle DeStefano, Barry Hafkin
| American Society for Microbiology (ASM)
In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis Citation Shoen C, DeStefano M, Hafkin B, Cynamon M. 2018. In vitro and in vivo activities of contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother 62:e00493-18. https://doi.org/10.1128/AAC.00493-18.
Open in Who Shared Issue with article?
See all 3 articles